Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting

Published on Feb 13, 2020in Expert Opinion on Therapeutic Targets5.473
· DOI :10.1080/14728222.2020.1724285
Anne-Sophie Wattiez6
Estimated H-index: 6
(UI: University of Iowa),
Levi P. Sowers10
Estimated H-index: 10
(UI: University of Iowa),
Andrew F. Russo46
Estimated H-index: 46
(UI: University of Iowa)
ABSTRACTIntroduction: The neuropeptide calcitonin gene-related peptide (CGRP) is recognized as a critical player in migraine pathophysiology. Excitement has grown regarding CGRP because of the deve...
📖 Papers frequently viewed together
9 Citations
56 Citations
1 Citations
#1Charles M. ConwayH-Index: 12
#2Robert CroopH-Index: 5
Last. Richard B. Lipton (Albert Einstein College of Medicine)H-Index: 178
view all 5 authors...
Objective: Characterize the cardiovascular (CV) safety of rimegepant, a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist, in nonclinical assays and clinical trials. Background: Approximately 3.5 million individuals with migraine have had a CV event, condition, or procedure that contraindicates triptan treatment. A single oral 75 mg dose of rimegepant has demonstrated efficacy in 3 Phase 3 trials for the acute treatment of migraine (Studies 301, 302, and 303). Design/Meth...
6 Citations
Abstract Background Ubrogepant is an oral, small-molecule calcitonin gene–related peptide receptor antagonist for acute migraine treatment. Methods We conducted a randomized trial to evaluate the e...
103 CitationsSource
#1Richard B. Lipton (Albert Einstein College of Medicine)H-Index: 178
#2David W. Dodick (Mayo Clinic)H-Index: 15
Last. Joel M. TrugmanH-Index: 5
view all 7 authors...
Importance Ubrogepant is an oral calcitonin gene–related peptide receptor antagonist under investigation for acute treatment of migraine. Objective To evaluate the efficacy and tolerability of ubrogepant compared with placebo for acute treatment of a single migraine attack. Design, Setting, and Participants Phase 3, multicenter, randomized, double-blind, placebo-controlled, single-attack, clinical trial (ACHIEVE II) conducted in the United States (99 primary care and research clinics; August 26,...
84 CitationsSource
#1Jacob C. A. Edvinsson (Copenhagen University Hospital)H-Index: 4
#2Karin Warfvinge (Copenhagen University Hospital)H-Index: 27
Last. Kristian Agmund Haanes (Copenhagen University Hospital)H-Index: 19
view all 7 authors...
Monoclonal antibodies (mAbs) towards CGRP or the CGRP receptor show good prophylactic antimigraine efficacy. However, their site of action is still elusive. Due to lack of passage of mAbs across the blood-brain barrier the trigeminal system has been suggested a possible site of action because it lacks blood-brain barrier and hence is available to circulating molecules. The trigeminal ganglion (TG) harbors two types of neurons; half of which store CGRP and the rest that express CGRP receptor elem...
30 CitationsSource
#1Karl Messlinger (FAU: University of Erlangen-Nuremberg)H-Index: 39
#2Andrew F. Russo (UI: University of Iowa)H-Index: 46
IntroductionThe trigeminal ganglion is unique among the somatosensory ganglia regarding its topography, structure, composition and possibly some functional properties of its cellular components. Be...
29 CitationsSource
#1Peter J. Goadsby ('KCL': King's College London)H-Index: 137
#2Stewart J. Tepper (Dartmouth College)H-Index: 61
Last. Abhijeet JakateH-Index: 4
view all 11 authors...
BackgroundUbrogepant is a novel, oral calcitonin gene–related peptide (CGRP) receptor antagonist in development for the acute treatment of migraine. This trial evaluated the safety and tolerability...
21 CitationsSource
#1Robert CroopH-Index: 5
#2Peter J. Goadsby (UCSF: University of California, San Francisco)H-Index: 137
Last. Richard B. Lipton (Albert Einstein College of Medicine)H-Index: 178
view all 8 authors...
Summary Background Rimegepant, a small molecule calcitonin gene-related peptide receptor antagonist, has shown efficacy in the acute treatment of migraine using a standard tablet formulation. The objective of this trial was to compare the efficacy, safety, and tolerability of a novel orally disintegrating tablet formulation of rimegepant at 75 mg with placebo in the acute treatment of migraine. Methods In this double-blind, randomised, placebo-controlled, multicentre phase 3 trial, adults aged 1...
98 CitationsSource
#1Stephen Aradi (UPenn: University of Pennsylvania)H-Index: 1
#2Eric A. Kaiser (UPenn: University of Pennsylvania)H-Index: 9
Last. Brett Cucchiara (UPenn: University of Pennsylvania)H-Index: 32
view all 3 authors...
Abstract Calcitonin gene-related peptide (CGRP) is involved in nociception and neurogenic inflammation in migraine, but also serves as a potent vasodilator acting on intracranial arteries. This latter effect raises concern about the possibility of drugs inhibiting CGRP precipitating cerebral ischemia. We describe a 41-year-old woman with migraine without aura who developed a right thalamic infarction following a first dose of erenumab, a CGRP-receptor blocker. Stroke onset occurred during a typi...
17 CitationsSource
#1Richard B. Lipton (Albert Einstein College of Medicine)H-Index: 178
#2Robert CroopH-Index: 5
Last. Peter J. GoadsbyH-Index: 137
view all 10 authors...
Abstract Background Calcitonin gene–related peptide receptor has been implicated in the pathogenesis of migraine. Rimegepant is an orally administered, small-molecule, calcitonin gene–related pepti...
105 CitationsSource
#1Luana LionettoH-Index: 22
#2Martina Curto (Sapienza University of Rome)H-Index: 19
Last. Paolo Martelletti (Sapienza University of Rome)H-Index: 47
view all 7 authors...
ABSTRACTIntroduction: The Calcitonin Gene-Related Peptide (CGRP) has been implicated in migraine pathophysiology due to its role in neurogenic inflammation and transmission of trigeminovascular noc...
10 CitationsSource
Cited By13
#1Eva M a Sánchez‐Robles (CSIC: Spanish National Research Council)H-Index: 3
#2Rocío GirónH-Index: 11
Last. Carlos GoicoecheaH-Index: 14
view all 6 authors...
Chronic pain remains a major problem worldwide, despite the availability of various non-pharmacological and pharmacological treatment options. Therefore, new analgesics with novel mechanisms of action are needed. Monoclonal antibodies (mAbs) are directed against specific, targeted molecules involved in pain signaling and processing pathways that look to be very effective and promising as a novel therapy in pain management. Thus, there are mAbs against tumor necrosis factor (TNF), nerve growth fa...
#1Abubker Omaer (UA: University of Arizona)
#2Fahad M. Aldosari (UA: University of Arizona)
view all 6 authors...
What is known and objectives null Migraine is a disabling disorder that affects individuals of all ages. To date, there are multiple limitations to using guidelines-recommended treatments and preventive therapies. The goal of this review was to provide a comprehensive clinical review of the safety, efficacy and prescribing information of the emerging calcitonin gene-related peptide (CGRP) antagonists. Agents in this new pharmacologic class were approved by the US Food and Drug Administration (FD...
#1Pei Feng LimH-Index: 9
view all 3 authors...
PURPOSE OF REVIEW This article summarizes the current understanding of the pathophysiology of migraine, including some controversial aspects of the underlying mechanisms of the disorder. RECENT FINDINGS Recent functional neuroimaging studies focusing on the nonpainful symptoms of migraine have identified key areas of the central nervous system implicated in the early phases of a migraine attack. Clinical studies of spontaneous and provoked migraine attacks, together with preclinical studies usin...
Migraine is a complex neurological disorder that affects three times more women than men and can be triggered by endogenous and exogenous factors. Stress is a common migraine trigger and exposure to early life stress increases the likelihood of developing chronic pain disorders later in life. Here, we used our neonatal maternal separation (NMS) model of early life stress to investigate whether female NMS mice have an increased susceptibility to evoked migraine-like behaviors and the potential th...
#1Brandon J. Rea (Roy J. and Lucille A. Carver College of Medicine)H-Index: 4
#2Levi P. Sowers (Roy J. and Lucille A. Carver College of Medicine)H-Index: 10
Last. Andrew F. Russo (Roy J. and Lucille A. Carver College of Medicine)H-Index: 46
view all 8 authors...
We developed an automated squint assay using both black C57BL/6J and white CD1 mice that measured the interpalpebral fissure area between the upper and lower eyelids as an objective quantification of pain. In C57BL/6J mice, we observed a squint response to increasing doses of a migraine trigger, the neuropeptide CGRP, including a significant response in female mice at a dose below detection by the manual grimace scale. Using the automated software, both C57BL/6J and CD1 mice lacked a detectable ...
1 CitationsSource
#2William C. Castonguay (UI: University of Iowa)H-Index: 2
Last. Andrew F. RussoH-Index: 46
view all 12 authors...
ABSTRACT Chronic complications of traumatic brain injury represent one of the greatest financial burdens and sources of suffering in the society today. A substantial number of these patients suffer from posttraumatic headache (PTH), which is typically associated with tactile allodynia. Unfortunately, this phenomenon has been understudied, in large part because of the lack of well-characterized laboratory animal models. We have addressed this gap in the field by characterizing the tactile sensory...
5 CitationsSource
#1Brandon Baksh (UM: University of Miami)H-Index: 1
#2Julia Costa Garcia (UM: University of Miami)
Last. Anat Galor (UM: University of Miami)H-Index: 24
view all 3 authors...
Dry eye and migraine are common diseases with large societal and economic burdens that have recently been associated in the literature. This review outlines the link between dry eye and migraine, which may have implications for reducing their respective burdens. We highlight possible shared pathophysiology, including peripheral and central sensitization, as the potential link between dry eye and migraine. Finally, therapies targeting similar pathophysiological mechanisms between dry eye and migr...
#1Fatemeh Ramezani (IUMS: Iran University of Medical Sciences)H-Index: 11
#2Ali Neshasteh-Riz (IUMS: Iran University of Medical Sciences)H-Index: 10
Last. Michael R. Hamblin (UJ: University of Johannesburg)H-Index: 128
view all 6 authors...
Photobiomodulation therapy (PBMT) previously known as low-level laser therapy (LLLT) has been used for over 30 years, to treat neurological diseases. Low-powered lasers are commonly used for clinical applications, although recently LEDs have become popular. Due to the growing application of this type of laser in brain and neural-related diseases, this review focuses on the mechanisms of laser action. The most important points to consider include the photon absorption by intracellular structures;...
2 CitationsSource
#1Mengya WangH-Index: 2
Last. Andrew F. RussoH-Index: 46
view all 3 authors...